Implications of finding synergic in vitro drug-drug interactions between interferon-alpha and ribavirin for the treatment of hepatitis C virus.
D000998:Antiviral Agents / Q000494:pharmacology* / Q000627:therapeutic use*; D002478:Cells, Cultured; D004357:Drug Synergism; D016174:Hepacivirus / Q000187:drug effects*; D006526:Hepatitis C / Q000188:drug therapy*; D006801:Humans; D007370:Interferon Type I / Q000494:pharmacology* / Q000627:therapeutic use*; D011994:Recombinant Proteins; D012254:Ribavirin / Q000494:pharmacology* / Q000627:therapeutic use*; D014779:Virus Replication / Q000187:drug effects
D000998:Antiviral Agents; D007370:Interferon Type I; D011994:Recombinant Proteins; D012254:Ribavirin